Scheiner, Bernhard; Kang, Beodeul; Balcar, Lorenz et al.
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapyHEPATOLOGY. Bd. 81. H. 6. 2024 S. 1714-1727
Bauer, Ulrike; Ben Khaled, Najib; Grottenthaler, Julia M. et al.
Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitor-based therapy-first results from an international multicenter registryJOURNAL OF HEPATOLOGY. Bd. 80. 2024 S. S440-S441
Keggenhoff, Friederike L.; Castven, Darko; Becker, Diana et al.
PARP-1 selectively impairs <i>KRAS</i>-driven phenotypic and molecular features in intrahepatic cholangiocarcinomaGUT. Bd. 73. H. 10. 2024 S. 1712-1724
Janjigian, Yelena Y.; Al-Batran, Salah-Eddin; Wainberg, Zev A. et al.
Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN studyJOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 3_SUPPL. 2024 S. 245-246
Moehler, Markus; Janjigian, Yelena; Al-Batran, Salah-Eddin et al.
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN studyONCOLOGY RESEARCH AND TREATMENT. Bd. 47. 2024 S. 229-229
Molena, Daniela; Janjigian, Yelena; Al-Batran, Salah-Eddin et al.
PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): INTERIM RESULTS OF THE GLOBAL, PHASE 3 MATTERHORN STUDYGASTROENTEROLOGY. Bd. 166. H. 5. 2024 S. S996-S996
Janjigian, Yelena Y.; Al-Batran, Salah-Eddin; Wainberg, Zen A. et al.
Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN studyANNALS OF SURGICAL ONCOLOGY. Bd. 31. H. 1. 2024 S. S44-S45
Sangro, Bruno; Galle, Peter R.; Kelley, Robin Kate et al.
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular CarcinomaJOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 23. 2024
Klempner, Samuel J.; Cowden, Eric S.; Cytryn, Samuel L. et al.
PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 AssaysJCO PRECISION ONCOLOGY. Bd. 8. 2024
Klempner, Samuel J.; Cowden, Eric S.; Cytryn, Samuel Louis et al.
PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assaysJOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 16. 2024